Trial · NCT05946564
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
NCT05946564, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial. Trials, record NCT05946564. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05946564
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
- NCT number
- NCT05946564
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 126 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis
- Interventions
- Pioglitazone (ACTOS®), Placebo of Pioglitazone
- First posted
- 2023-07-14
- Last updated
- 2026-07-01
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Appearance of a success defined as (1) Delta sCreat > 30% (between D0 and week 26) AND (2) urine protein-to-creatinine (uPCR) < 1g/mmol | Week 26 | |
| Secondary | Change of renal function | Weeks 4, 12, 26 and 52 | Delta sCreat (baseline sCreat - follow-up sCreat) |
| Secondary | Proteinuria ratio | Weeks 4, 12, 26 and 52 | Spot urine protein-to-creatinine ratio (uPCR) |
| Secondary | Score VDI (Vasculitis Damage Index) | Week 26 and 52 | Systemic chronic damage due to vasculitis and treatment of vasculitis Min : 0 Max : 62 the best score is 0 |
| Secondary | Renal vasculitis activity | Weeks 4, 12, 26 and 52 | measurement of urine biomarkers: MCP-1 |
| Secondary | Renal vasculitis activity | Weeks 4, 12, 26 and 52 | measurement of urine biomarkers: KIM-1 |
| Secondary | Renal vasculitis activity | Weeks 4, 12, 26 and 52 | measurement of urine biomarkers: Calprotectin |
| Secondary | Renal vasculitis activity | Weeks 4, 12, 26 and 52 | measurement of urine biomarkers: CD163 |
| Secondary | Systemic vasculitis activity : score BVAS | Weeks 4, 12, 26 and 52 | BVAS (Birmingham Vasculitis Activity Score ), ANCA positivity Min : 0 Max : 63 The best score is 0 |
| Secondary | Refractory vasculitis | Weeks 12, 26 and 52 | Percentage of patients with refractory vasculitis and early vasculitis relapses |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05946564
GET https://conductscience.org/api/trials/v1/NCT05946564/registered